Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2025-04-11 Annual Report
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Annual Report 2024
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2024' which translates to 'Annual Report 2024' in Swedish. It contains detailed sections typical of an annual report such as business overview, management discussion, financial information, risk management, governance report, board and management details, financial notes, audit report, and signatures. It discusses the company's operations, clinical study results, financial position, and future outlook for the year 2024. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-11 Swedish
Kallelse till årsstämma i Ascelia Pharma AB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Kallelse till årsstämma' (Notice of Annual General Meeting) for Ascelia Pharma AB. It contains the agenda, proposals for board elections, remuneration, and other shareholder voting items. This document is a formal solicitation of proxies and information provided to shareholders ahead of the meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-04-04 Swedish
Notice of Annual General Meeting in Ascelia Pharma AB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' for Ascelia Pharma AB. It outlines the agenda, proposed resolutions, and procedures for shareholder participation. This document is a classic proxy solicitation and meeting notice, which falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on board elections, remuneration, and incentive programs.
2025-04-04 English
The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025
Capital/Financing Update Classification · 95% confidence The document is a press release from Ascelia Pharma announcing the determination of the subscription price for warrants (Series TO 1) and the initiation of the exercise period. It details the financial terms, the impact on share capital, and instructions for shareholders to exercise their warrants. This falls under the category of capital and financing updates, as it relates to the company's capital structure and the exercise of financial instruments (warrants).
2025-03-31 English
Teckningskursen för teckningsoptioner serie TO 1 i Ascelia Pharma har fastställts till 2,15 SEK och nyttjandeperioden inleds den 1 april 2025
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Ascelia Pharma announcing the final subscription price (2.15 SEK) for warrants (serie TO 1) and the commencement of the exercise period. This relates directly to capital structure changes and the issuance of new shares upon warrant exercise. While it mentions the availability of a prospectus, the core content is the announcement of the warrant exercise terms, which falls under the 'Share Issue/Capital Change' category.
2025-03-31 Swedish
Ascelia Pharma meddelar positivt utfall från FDA-möte och bekräftar planen att insända ansökan om marknadsgodkännande (NDA) för Orviglance i mitten 2025
Legal Proceedings Report Classification · 99% confidence The document is a short press release (3787 characters) announcing positive feedback from an FDA meeting regarding the NDA submission plan for a drug (Orviglance) scheduled for mid-2025. It contains a concluding section titled 'Bifogade filer' (Attached files) which links to a PDF document. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document is short and announces that a report/information is attached or published, it should be classified as a Report Publication Announcement (RPA) rather than the underlying report itself. This announcement serves to publish the news and point to the full details, fitting the RPA definition best.
2025-03-18 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.